Targeting c-Myb expression in human disease

Bibliography

• CLARK RE: Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia (2000) 14:347–355.
   PubMed Web of Science ®Google Scholar
• GONDA TJ, GOUGH NM, DUNN AR,DE BLAQUIERE J: Nucleotide sequence of cDNA clones of the murine myb proto-oncogene. EMBO J. (1985) 4:2003–2008.
   PubMed Web of Science ®Google Scholar
• WESTON KM: The myb genes. Semiri. Cancer Biol. (1990) 1:371–382.
   PubMedGoogle Scholar
• WESTON K: Myb proteins in life, death and differentiation. Curr. Opiri. Genet. Dev. (1998) 8:76–81.
   PubMed Web of Science ®Google Scholar
• NESS SA: Myb binding proteins: regulators and cohorts in transformation. Oricogerie (1999) 18:3039–3046.
   Google Scholar
• KLEMPNAUER KH, GONDA TJ, BISHOP JM: Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: the architecture of a transduced oncogene. Cell (1982) 31:453–463.
   PubMed Web of Science ®Google Scholar
• WESTIN EH, WONG-STAAL F, GELMANN EP et al.: Expression of cellular homologues of retroviral onc genes in human hematopoietic cells. Proc. Natl. Acad. Sci. USA (1982) 79:2490–2494.
   PubMed Web of Science ®Google Scholar
• DUPREY SP, BOETTIGER D: Developmental regulation of c-myb in normal myeloid progenitor cells. Proc. Natl. Acad. Li. USA (1985) 82:6937–6941.
   PubMed Web of Science ®Google Scholar
• FU SL, LIPSICK JS: Constitutive expression of full-length c-Myb transforms avian cells characteristic of both the monocytic and granulocytic lineages. Cell Growth Differ (1997) 8:35–45.
   PubMedGoogle Scholar
• GONDA TJ, RAMSAY RG, JOHNSON GR: Murine myeloid cell lines derived by in vitro infection with recombinant c-myb retroviruses express myb from rearranged vector proviruses. EMBOJ (1989) 8:1767–1775.
   PubMed Web of Science ®Google Scholar
• •This is the first study showing that c-Myb could transform mammalian cells, and extended the work of others using avian retroviruses that transform chicken haematopoietic cells.
   Google Scholar
• GONDA TJ, BUCKMASTER C, RAMSAY RG: Activation of c-myb by carboxy-terminal truncation: relationship to transformation of murine haemopoietic cells in vitro. EMBO J. (1989) 8:1777–1783.
   PubMed Web of Science ®Google Scholar
• MUCENSKI ML, MCLAIN K, KIER AB etal.: A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell (1991) 65:677–689.
   Google Scholar
• ••This seminal mouse knockout studyconfirmed the essential role of c-Myb in mouse development.
   Google Scholar
• SICURELLA C, FREEMAN R, MICALLEF S, MUCENSKI ML, BERTONCELLO I, RAMSAY RG: Defective stem cell factor expression in c-myb null fetal liver stroma. Blood Cells Mol. Dis. (2001) 27:470–478.
   PubMed Web of Science ®Google Scholar
• THOMPSON MA, ROSENTHAL MA, ELLIS SL et al.: c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bc1-2 expression. Cancer Res. (1998) 58:5168–5175.
   PubMed Web of Science ®Google Scholar
• ALEXANDER RJ, BUXBAUM JN, RAICHT RF: Oncogene alterations in rat colon tumors induced by N-methyl-N-nitrosourea. Am. J. Med. Li. (1992) 303:16–24.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL MA, THOMPSON MA, ELLIS S, WHITEHEAD RH, RAMSAY RG: Colonic expression of c-myb is initiated in utero and continues throughout adult life. Cell Growth Differ. (1996) 7:961–967.
   PubMedGoogle Scholar
• ZORBAS M, SICURELLA C, BERTONCELLO I et al.: c-Myb is critical for murine colon development. Oricogerie (1999) 18:5821–5830.
   Google Scholar
• •This study was the first to directly show a role of c-Myb in colon development and apoptosis.
   Google Scholar
• THOMPSON MA, RAMSAY RG: Myb: an old oncoprotein with new roles. Bioessays (1995) 17:341–350.
   PubMed Web of Science ®Google Scholar
• MELANI C, RIVOLTINI L, PARMIANI G, CALABRETTA B, COLOMBO MP: Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res. (1991) 51:2897–2901.
   PubMed Web of Science ®Google Scholar
• RAMSAY RG, THOMPSON MA, HAYMAN JA, REID G, GONDA TJ, WHITEHEAD RH: Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ (1992) 3:723–730.
   PubMedGoogle Scholar
• BIROCCIO A, BENASSI B, D'AGNANO I et al.: c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am. I Pathol. (2001) 158:1289–1299.
   Google Scholar
• ••This study showed the importance ofover-expression of c-Myb in colon cancer patient prognosis, and shows that Bcl-X is a potential c-myb target.
   Google Scholar
• SU AT, WELSH JB, SAPINOSO LM etal.: Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. (2001) 61:7388–7393.
   Google Scholar
• JOHNSTONE CN, TEBBUTT NC, ABUD HE et al.: Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am. I Physiol. Castrointest. Liver Physiol. (2000) 279:G500–G510.
   Web of Science ®Google Scholar
• GUERIN M, SHENG ZM, ANDRIEU N, RIOU G: Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oricogene (1990) 5:131–135.
   PubMed Web of Science ®Google Scholar
• KAURANIEMI P, HEDENFALK I, PERSSON K et al.: MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. (2000) 60:5323–5328.
   PubMed Web of Science ®Google Scholar
• ALEXANDER RJ, BUXBAUM JN, RAICHT RF: Enhanced expression of oncogene-encoded mRNA in a rat model of colon cancer. Am. J Med. Li. (1991) 301:238–245.
   PubMed Web of Science ®Google Scholar
• ALEXANDER RJ, PANJA A, KAPLAN-LISS E, MAYER L, RAICHT RF: Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease. Dig. Dis. Sci. (1996) 41:660–669.
   PubMed Web of Science ®Google Scholar
• ALITALO K, WINQVIST R, UN CC, DE LA CHAPELLE A, SCHWAB M, BISHOP JM: Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc. Nati Acad. Sci. USA (1984) 81:4534–4538.
   PubMed Web of Science ®Google Scholar
• •This paper was the first to suggest that c-Myb may have been important in epithelial cancers. It also showed c-Myb amplification.
   Google Scholar
• BRABENDER J, LORD RV, DANENBERG KD et al.: Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surg. Res. (2001) 99:301–306.
   PubMed Web of Science ®Google Scholar
• BAER MR, AUGUSTINOS P, KINNIBURGH AJ: Defective c-myc and c-myb RNA turnover in acute myeloid leukemia cells. Blood (1992) 79:1319–1326.
   PubMed Web of Science ®Google Scholar
• THOMPSON MA, FLEGG R, WESTIN EH, RAMSAY RG: Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines. Oricogene (1997) 14:1715–1723.
   PubMed Web of Science ®Google Scholar
• MECHTI N, PIECHACZYK M, BLANCHARD JM, JEANTEUR E LEBLEU B: Sequence requirements for premature transcription arrest within the first intron of the mouse c-fos gene. Mol. Cell. Biol. (1991) 11:2832–2841.
   PubMed Web of Science ®Google Scholar
• KEENE RG, MUELLER A, LANDICK R, LONDON L: Transcriptional pause, arrest and termination sites for RNA polymerase II in mammalian N- and c-myc genes. Nucleic Acids Res. (1999) 27:3173–3182.
   PubMed Web of Science ®Google Scholar
• XU L, MENG Y, WALLEN R, DEPINHO RA: Loss of transcriptional attenuation in N-myc is associated with progression towards a more malignant phenotype. Oricogerie (1995) 11:1865–1872.
   Google Scholar
• WEAVER GA, TANGEL CT, KRAUSE JA etal.: Biomarkers of human colonic cell growth are influenced differently by a history of colonic neoplasia and the consumption of acarbose.j. Num (2000) 130:2718–2725.
   Google Scholar
• COHEN LA, AMIN S, MARKS PA, RIFKIND RA, DESAI D, RICHON VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. (1999) 19:4999–5005.
   PubMed Web of Science ®Google Scholar
• FRAMPTON J, RAMQVIST T, GRAF T: v-Myb of E26 leukemia virus up-regulates bc1-2 and suppresses apoptosis in myeloid cells. Genes Dev. (1996) 10:2720–2731.
   PubMed Web of Science ®Google Scholar
• TAYLOR D, BADIANI E WESTON K: A dominant interfering Myb mutant causes apoptosis in T cells. Genes Dev. (1996) 10:2732–2744.
   PubMed Web of Science ®Google Scholar
• COGSWELL JP, COGSWELL PC, KUEHL WM et al.: Mechanism of c-myc regulation by c-Myb in different cell lineages. Mol. Cell. Biol. (1993) 13:2858–2869.
   PubMed Web of Science ®Google Scholar
• NAKAGOSHI H, KANEI-ISHII C, SAWAZAKI T, MIZUGUCHI G, ISHII S: Transcriptional activation of the c-myc gene by the c-myb and B-myb gene products. Oricogerie (1992) 7:1233–1240.
   Google Scholar
• SCHMIDT M, NAZAROV V, STEVENS L, WATSON R, WOLFF L: Regulation of the resident chromosomal copy of c-myc by c-Myb is involved in myeloid leukemogenesis. Mol. Cell. Biol. (2000) 20:1970–1981.
   PubMed Web of Science ®Google Scholar
• RAMSAY RG, FRIEND A, VIZANTIOS Yet al.: Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. (2000) 60:1805–1809.
   Google Scholar
• TANIKAWA J, ICHIKAWA-IWATA E, KANEI-ISHII C, ISHII S: Regulation of c-Myb activity by tumor suppressor p53. Blood Cells Mol. Dis. (2001) 27:479–482.
   PubMed Web of Science ®Google Scholar
• DASGUPTA P, SAIKUMAR P, REDDY CD, REDDY EP: Myb protein binds to human immunodeficiency virus 1 long terminal repeat (LTR) sequences and transactivates LTR-mediated transcription. Proc. Nati Acad. Sci. USA (1990) 87:8090–8094.
   PubMed Web of Science ®Google Scholar
• CHURCHILL MJ, RAMSAY RG, RHODES DI, DEACON NJ: c-Myb influences HIV type 1 gene expression and virus production. AIDS Res. Hum. Retroviruses (2001) 17:1481–1488.
   PubMed Web of Science ®Google Scholar
• •This study suggested that c-Myb was important to the HIV life cycle, and that antisense ODNs were effective in inhibiting the virus.
   Google Scholar
• PASTORINO F, STUART D, PONZONI M, ALLEN TM: Targeted delivery of antisense oligonucleotides in cancer. I Control Release (2001) 74:69–75.
   PubMed Web of Science ®Google Scholar
• PRINS J, DE VRIES EG, MULDER NH: The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. (1993) 13:1373–1385.
   PubMed Web of Science ®Google Scholar
• GILES RV, SPILLER DG, TIDD DM: Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anticancer Drug Des. (1993) 8:33–51.
   PubMedGoogle Scholar
• GEWIRTZ AM, SOKOL DL, RATAJCZAK MZ: Nucleic acid therapeutics: state of the art and future prospects. Blood (1998) 92:712–736.
   PubMed Web of Science ®Google Scholar
• STEIN CA: The experimental use of antisense oligonucleotides: a guide for the perplexed. Clio. Invest. (2001) 108:641–644.
   PubMed Web of Science ®Google Scholar
• MILLER PS: Oligonucleoside methylphosphonates as antisense reagents. Biotechnology (NY) (1991) 9:358–362.
   PubMedGoogle Scholar
• SUMMERTON J: Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta (1999) 1489:141–158.
   PubMed Web of Science ®Google Scholar
• STEIN CA: Anti-sense oligodeoxynucleotides - promises and pitfalls. Leukemia (1992) 6:967–974.
   PubMed Web of Science ®Google Scholar
• STEIN CA, SUBASINGHE C, SHINOZUKA K, COHEN JS: Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acid Res. (1988) 16:3209–3221.
   PubMed Web of Science ®Google Scholar
• MATSUKURA M, SHINOZUKA K, ZON G et al.: Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA (1987) 84:7706–7710.
   PubMed Web of Science ®Google Scholar
• GAO WY, STORM C, EGAN W, CHENG YC: Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. PharmacoL (1993) 43:45–50.
   Web of Science ®Google Scholar
• STEIN CA, CHENG YC: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (1993) 261:1004–1012.
   PubMed Web of Science ®Google Scholar
• AKHTAR S, BASU S, WICKSTROM E, JULIANO RL: Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acid Res. (1991) 19:5551–5559.
   PubMed Web of Science ®Google Scholar
• BENNETT CF, CHIANG MY, CHAN H, SHOEMAKER JE, MIRABELLI CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. PharmacoL (1992) 41:1023–1033.
   PubMed Web of Science ®Google Scholar
• COLIGE A, SOKOLOV BP, NUGENT P,BASERGA R, PROCKOP DJ: Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. Biochemistry (1993) 32:7–11.
   PubMed Web of Science ®Google Scholar
• KRONENWETT R, STEIDL U, KIRSCH M, SCZAKIEL G, HAAS R: Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood (1998) 91:852–862.
   PubMed Web of Science ®Google Scholar
• HENRY SP, GICLAS PC, LEEDS J et al.:Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. PharmacoL Exp. Ther. (1997) 281:810–816.
   PubMed Web of Science ®Google Scholar
• WEBB A, CUNNINGHAM D, COTTER F et al.: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349:1137–1141.
   PubMed Web of Science ®Google Scholar
• ••This milestone paper provides preliminaryclinical evidence that antisense therapy works in humans.
   Google Scholar
• STUART DD, ALLEN TM: A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta (2000) 1463:219–229.
   PubMed Web of Science ®Google Scholar
• XU Y, SZOKA FC Jr: Mechanism of DNA release from cationic liposomeMNA complexes used in cell transfection. Biochemistry (1996) 35:5616–5623.
   PubMed Web of Science ®Google Scholar
• TONKINSON JL, STEIN CA: Patterns of intracellular compartmentalization, trafficking and acidification of 5 "-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. (1994) 22:4268–4275.
   PubMed Web of Science ®Google Scholar
• ZELPHATI O, SZOKA FC Jr: Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA (1996) 93:11493–11498.
   PubMed Web of Science ®Google Scholar
• BURGESS TL, FISHER EF, ROSS SL et al.: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA (1995) 92:4051–4055.
   PubMed Web of Science ®Google Scholar
• ••This frequenctly cited paper is responsiblefor highlighting the role of the G-quartet sequence that affords non-sequence-specific toxicity by ODNs. Unfortunately, it is also used by some to dismiss the entire field of antisense technology.
   Google Scholar
• SAIJO Y, UCHIYAMA B, ABE T, SATOH K, NUKIWA T: Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition. Jpri. J. Cancer Res. (1997) 88:26–33.
   PubMedGoogle Scholar
• BENIMETSKAYA L, BERTON M, KOLBANOVSKY A, BENIMETSKY S, STEIN CA: Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-icB p65) 'antisense' oligodeoxynucleotide. Nucleic Acids Res. (1997) 25:2648–2656.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO S, YAMAMOTO T, KATAOKA T, KURAMOTO E, YANO O, TOKUNAGA T: Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J. ImmurioL (1992) 148:4072–4076.
   PubMed Web of Science ®Google Scholar
• KRIEG AM, YI AK, MATSON S et al.: CpGmotifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546–549.
   PubMed Web of Science ®Google Scholar
• KRIEG AM, MATSON S, FISHER E: Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. (1996) 6:133–139.
   PubMedGoogle Scholar
• NEURATH MF, PETTERSSON S, MEYER ZUM BUSCHENFELDE KH, STROBER W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-icB abrogates established experimental colitis in mice. Nat. Med. (1996) 2:998–1004.
   PubMed Web of Science ®Google Scholar
• DEL BUFALO D, CUCCO C, LEONETTI C et al.: Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br. J. Cancer (1996) 74:387–393.
   PubMed Web of Science ®Google Scholar
• •This study sets the scene for the future of antisense ODNs in cancer, as it shows the advantages of employing ODNs with conventional chemotherapy in vivo.
   Google Scholar
• FLAHERTY KT, STEVENSON JP, O'DWYER PJ: Antisense therapeutics: lessons from early clinical trials. Curr. Opiri. °ma. (2001) 13:499–505.
   Google Scholar
• MONIA BE JOHNSTON JF, GEIGER T, MULLER M, FABBRO D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. (1996) 2:668–675.
   PubMed Web of Science ®Google Scholar
• OFFENSPERGER WB, OFFENSPERGER S, WALTER E et al.: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. (1993) 12:1257–1262.
   PubMed Web of Science ®Google Scholar
• STATHAM S, MORGAN RA: Gene therapy clinical trials for HIV. Cum: Opiri. Mol. Ther. (1999) 1:430–436.
   PubMedGoogle Scholar
• FIELD AK: Oligonucleotides as inhibitors of human immunodeficiency virus. Cum: Opiri. Mol. Ther. (1999) 1:323–331.
   PubMed Web of Science ®Google Scholar
• ROBERTSON DL, ANDERSON JP, BRADAC JA et al.: HIV-1 nomenclature proposal. Science (2000) 288:55–56.
   PubMed Web of Science ®Google Scholar
• BAYEVER E, IVERSEN PL, BISHOP MR et al: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial. Antisense Res. Dev. (1993) 3:383–390.
   PubMedGoogle Scholar
• LUGER SM, O'BRIEN SG, RATAJCZAK J et al: Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood (2002) 99:1150–1158.
   PubMed Web of Science ®Google Scholar
• ••This is a key study showing the application of antisense c-Myb ODNs in a clincal trial setting.
   Google Scholar
• FUNATO T, SATOU J, KOZAWA K, FUJIMAKI S, MIURA T, KAKU M: Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin. Oncol Rep. (2001) 8:807–810.
   PubMed Web of Science ®Google Scholar
• CAMPANERO MR, ARMSTRONG M, FLEMINGTON E: Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol. Cell. Biol. (1999) 19:8442–8450.
   PubMed Web of Science ®Google Scholar
• BENDER TI THOMPSON CB, KUEHL WM: Differential expression of c-myb mRNA in murine B lymphomas by a block to transcription elongation. Science (1987) 237:1473–1476.
   PubMed Web of Science ®Google Scholar
• WATSON RJ: A transcriptional arrest mechanism involved in controlling constitutive levels of mouse c-myb mRNA. Oncogene (1988) 2:267–272.
   PubMed Web of Science ®Google Scholar
• CHUBB JM, HOGAN ME: Human therapeutics based on triple helix technology. Trends Biotech. (1992) 10:132–136.
   PubMed Web of Science ®Google Scholar
• MERCOLA D, COHEN JS: Antisense approaches to cancer gene therapy. Cancer Gene Ther. (1995) 2:47–59.
   PubMed Web of Science ®Google Scholar
• SUMMERTON J, WELLER D: Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. (1997) 7:187–195.
   PubMedGoogle Scholar
• NISHIKURA K: A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. Cell (2001) 107:415–418.
   PubMed Web of Science ®Google Scholar
• STEIN CA, NARAYANAN R: Antisense oligodeoxynucleotides. Cun: Opin. Otani (1994) 6:587–594.
   PubMedGoogle Scholar